Report Overview
This report provides a deep insight into the global Psychedelic Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Psychedelic Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Psychedelic Drugs market in any manner.
Global Psychedelic Drugs Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
COMPASS Pathways PLC
Pfizer
Eli Lilly
GlaxoSmithKline
Cybin Inc
Field Trip Health
ATAI Life Sciences
NUMINUS WELLNESS
MindMed
HAVN Life Sciences
Seelos Therapeutics
Jannsen
Acadia Pharmaceuticals
Intellipharmaceutics
Revive Therapeutics
Mydecine Innovations Group
Red Light Holland
Braxia Scientific
Mind Cure Health
Entheon Biomedical
Market Segmentation (by Type)
Psilocybin
LSD
MDMA
DMT
Ketamine
Others
Market Segmentation (by Application)
Depressive Disorders
Post-Traumatic Stress Disorders
Substance Abuse Disorders
Obsessive Compulsive Disorders
Others
Geographic Segmentation
? North America (USA, Canada, Mexico)
? Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
? Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
? South America (Brazil, Argentina, Columbia, Rest of South America)
? The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
? Industry drivers, restraints, and opportunities covered in the study
? Neutral perspective on the market performance
? Recent industry trends and developments
? Competitive landscape & strategies of key players
? Potential & niche segments and regions exhibiting promising growth covered
? Historical, current, and projected market size, in terms of value
? In-depth analysis of the Psychedelic Drugs Market
? Overview of the regional outlook of the Psychedelic Drugs Market:
Key Reasons to Buy this Report:
? Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
? This enables you to anticipate market changes to remain ahead of your competitors
? You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
? The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
? Provision of market value (USD Billion) data for each segment and sub-segment
? Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
? Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
? Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
? Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
? The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
? Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
? Provides insight into the market through Value Chain
? Market dynamics scenario, along with growth opportunities of the market in the years to come
? 6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Psychedelic Drugs Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Psychedelic Drugs
1.2 Key Market Segments
1.2.1 Psychedelic Drugs Segment by Type
1.2.2 Psychedelic Drugs Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Psychedelic Drugs Market Overview
2.1 Global Market Overview
2.1.1 Global Psychedelic Drugs Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Psychedelic Drugs Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Psychedelic Drugs Market Competitive Landscape
3.1 Global Psychedelic Drugs Sales by Manufacturers (2019-2024)
3.2 Global Psychedelic Drugs Revenue Market Share by Manufacturers (2019-2024)
3.3 Psychedelic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Psychedelic Drugs Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Psychedelic Drugs Sales Sites, Area Served, Product Type
3.6 Psychedelic Drugs Market Competitive Situation and Trends
3.6.1 Psychedelic Drugs Market Concentration Rate
3.6.2 Global 5 and 10 Largest Psychedelic Drugs Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Psychedelic Drugs Industry Chain Analysis
4.1 Psychedelic Drugs Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Psychedelic Drugs Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Psychedelic Drugs Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Psychedelic Drugs Sales Market Share by Type (2019-2024)
6.3 Global Psychedelic Drugs Market Size Market Share by Type (2019-2024)
6.4 Global Psychedelic Drugs Price by Type (2019-2024)
7 Psychedelic Drugs Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Psychedelic Drugs Market Sales by Application (2019-2024)
7.3 Global Psychedelic Drugs Market Size (M USD) by Application (2019-2024)
7.4 Global Psychedelic Drugs Sales Growth Rate by Application (2019-2024)
8 Psychedelic Drugs Market Segmentation by Region
8.1 Global Psychedelic Drugs Sales by Region
8.1.1 Global Psychedelic Drugs Sales by Region
8.1.2 Global Psychedelic Drugs Sales Market Share by Region
8.2 North America
8.2.1 North America Psychedelic Drugs Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Psychedelic Drugs Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Psychedelic Drugs Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Psychedelic Drugs Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Psychedelic Drugs Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 COMPASS Pathways PLC
9.1.1 COMPASS Pathways PLC Psychedelic Drugs Basic Information
9.1.2 COMPASS Pathways PLC Psychedelic Drugs Product Overview
9.1.3 COMPASS Pathways PLC Psychedelic Drugs Product Market Performance
9.1.4 COMPASS Pathways PLC Business Overview
9.1.5 COMPASS Pathways PLC Psychedelic Drugs SWOT Analysis
9.1.6 COMPASS Pathways PLC Recent Developments
9.2 Pfizer
9.2.1 Pfizer Psychedelic Drugs Basic Information
9.2.2 Pfizer Psychedelic Drugs Product Overview
9.2.3 Pfizer Psychedelic Drugs Product Market Performance
9.2.4 Pfizer Business Overview
9.2.5 Pfizer Psychedelic Drugs SWOT Analysis
9.2.6 Pfizer Recent Developments
9.3 Eli Lilly
9.3.1 Eli Lilly Psychedelic Drugs Basic Information
9.3.2 Eli Lilly Psychedelic Drugs Product Overview
9.3.3 Eli Lilly Psychedelic Drugs Product Market Performance
9.3.4 Eli Lilly Psychedelic Drugs SWOT Analysis
9.3.5 Eli Lilly Business Overview
9.3.6 Eli Lilly Recent Developments
9.4 GlaxoSmithKline
9.4.1 GlaxoSmithKline Psychedelic Drugs Basic Information
9.4.2 GlaxoSmithKline Psychedelic Drugs Product Overview
9.4.3 GlaxoSmithKline Psychedelic Drugs Product Market Performance
9.4.4 GlaxoSmithKline Business Overview
9.4.5 GlaxoSmithKline Recent Developments
9.5 Cybin Inc
9.5.1 Cybin Inc Psychedelic Drugs Basic Information
9.5.2 Cybin Inc Psychedelic Drugs Product Overview
9.5.3 Cybin Inc Psychedelic Drugs Product Market Performance
9.5.4 Cybin Inc Business Overview
9.5.5 Cybin Inc Recent Developments
9.6 Field Trip Health
9.6.1 Field Trip Health Psychedelic Drugs Basic Information
9.6.2 Field Trip Health Psychedelic Drugs Product Overview
9.6.3 Field Trip Health Psychedelic Drugs Product Market Performance
9.6.4 Field Trip Health Business Overview
9.6.5 Field Trip Health Recent Developments
9.7 ATAI Life Sciences
9.7.1 ATAI Life Sciences Psychedelic Drugs Basic Information
9.7.2 ATAI Life Sciences Psychedelic Drugs Product Overview
9.7.3 ATAI Life Sciences Psychedelic Drugs Product Market Performance
9.7.4 ATAI Life Sciences Business Overview
9.7.5 ATAI Life Sciences Recent Developments
9.8 NUMINUS WELLNESS
9.8.1 NUMINUS WELLNESS Psychedelic Drugs Basic Information
9.8.2 NUMINUS WELLNESS Psychedelic Drugs Product Overview
9.8.3 NUMINUS WELLNESS Psychedelic Drugs Product Market Performance
9.8.4 NUMINUS WELLNESS Business Overview
9.8.5 NUMINUS WELLNESS Recent Developments
9.9 MindMed
9.9.1 MindMed Psychedelic Drugs Basic Information
9.9.2 MindMed Psychedelic Drugs Product Overview
9.9.3 MindMed Psychedelic Drugs Product Market Performance
9.9.4 MindMed Business Overview
9.9.5 MindMed Recent Developments
9.10 HAVN Life Sciences
9.10.1 HAVN Life Sciences Psychedelic Drugs Basic Information
9.10.2 HAVN Life Sciences Psychedelic Drugs Product Overview
9.10.3 HAVN Life Sciences Psychedelic Drugs Product Market Performance
9.10.4 HAVN Life Sciences Business Overview
9.10.5 HAVN Life Sciences Recent Developments
9.11 Seelos Therapeutics
9.11.1 Seelos Therapeutics Psychedelic Drugs Basic Information
9.11.2 Seelos Therapeutics Psychedelic Drugs Product Overview
9.11.3 Seelos Therapeutics Psychedelic Drugs Product Market Performance
9.11.4 Seelos Therapeutics Business Overview
9.11.5 Seelos Therapeutics Recent Developments
9.12 Jannsen
9.12.1 Jannsen Psychedelic Drugs Basic Information
9.12.2 Jannsen Psychedelic Drugs Product Overview
9.12.3 Jannsen Psychedelic Drugs Product Market Performance
9.12.4 Jannsen Business Overview
9.12.5 Jannsen Recent Developments
9.13 Acadia Pharmaceuticals
9.13.1 Acadia Pharmaceuticals Psychedelic Drugs Basic Information
9.13.2 Acadia Pharmaceuticals Psychedelic Drugs Product Overview
9.13.3 Acadia Pharmaceuticals Psychedelic Drugs Product Market Performance
9.13.4 Acadia Pharmaceuticals Business Overview
9.13.5 Acadia Pharmaceuticals Recent Developments
9.14 Intellipharmaceutics
9.14.1 Intellipharmaceutics Psychedelic Drugs Basic Information
9.14.2 Intellipharmaceutics Psychedelic Drugs Product Overview
9.14.3 Intellipharmaceutics Psychedelic Drugs Product Market Performance
9.14.4 Intellipharmaceutics Business Overview
9.14.5 Intellipharmaceutics Recent Developments
9.15 Revive Therapeutics
9.15.1 Revive Therapeutics Psychedelic Drugs Basic Information
9.15.2 Revive Therapeutics Psychedelic Drugs Product Overview
9.15.3 Revive Therapeutics Psychedelic Drugs Product Market Performance
9.15.4 Revive Therapeutics Business Overview
9.15.5 Revive Therapeutics Recent Developments
9.16 Mydecine Innovations Group
9.16.1 Mydecine Innovations Group Psychedelic Drugs Basic Information
9.16.2 Mydecine Innovations Group Psychedelic Drugs Product Overview
9.16.3 Mydecine Innovations Group Psychedelic Drugs Product Market Performance
9.16.4 Mydecine Innovations Group Business Overview
9.16.5 Mydecine Innovations Group Recent Developments
9.17 Red Light Holland
9.17.1 Red Light Holland Psychedelic Drugs Basic Information
9.17.2 Red Light Holland Psychedelic Drugs Product Overview
9.17.3 Red Light Holland Psychedelic Drugs Product Market Performance
9.17.4 Red Light Holland Business Overview
9.17.5 Red Light Holland Recent Developments
9.18 Braxia Scientific
9.18.1 Braxia Scientific Psychedelic Drugs Basic Information
9.18.2 Braxia Scientific Psychedelic Drugs Product Overview
9.18.3 Braxia Scientific Psychedelic Drugs Product Market Performance
9.18.4 Braxia Scientific Business Overview
9.18.5 Braxia Scientific Recent Developments
9.19 Mind Cure Health
9.19.1 Mind Cure Health Psychedelic Drugs Basic Information
9.19.2 Mind Cure Health Psychedelic Drugs Product Overview
9.19.3 Mind Cure Health Psychedelic Drugs Product Market Performance
9.19.4 Mind Cure Health Business Overview
9.19.5 Mind Cure Health Recent Developments
9.20 Entheon Biomedical
9.20.1 Entheon Biomedical Psychedelic Drugs Basic Information
9.20.2 Entheon Biomedical Psychedelic Drugs Product Overview
9.20.3 Entheon Biomedical Psychedelic Drugs Product Market Performance
9.20.4 Entheon Biomedical Business Overview
9.20.5 Entheon Biomedical Recent Developments
10 Psychedelic Drugs Market Forecast by Region
10.1 Global Psychedelic Drugs Market Size Forecast
10.2 Global Psychedelic Drugs Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Psychedelic Drugs Market Size Forecast by Country
10.2.3 Asia Pacific Psychedelic Drugs Market Size Forecast by Region
10.2.4 South America Psychedelic Drugs Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Psychedelic Drugs by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Psychedelic Drugs Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Psychedelic Drugs by Type (2025-2030)
11.1.2 Global Psychedelic Drugs Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Psychedelic Drugs by Type (2025-2030)
11.2 Global Psychedelic Drugs Market Forecast by Application (2025-2030)
11.2.1 Global Psychedelic Drugs Sales (K Units) Forecast by Application
11.2.2 Global Psychedelic Drugs Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Psychedelic Drugs Market Size Comparison by Region (M USD)
Table 5. Global Psychedelic Drugs Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Psychedelic Drugs Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Psychedelic Drugs Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Psychedelic Drugs Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Psychedelic Drugs as of 2022)
Table 10. Global Market Psychedelic Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Psychedelic Drugs Sales Sites and Area Served
Table 12. Manufacturers Psychedelic Drugs Product Type
Table 13. Global Psychedelic Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Psychedelic Drugs
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Psychedelic Drugs Market Challenges
Table 22. Global Psychedelic Drugs Sales by Type (K Units)
Table 23. Global Psychedelic Drugs Market Size by Type (M USD)
Table 24. Global Psychedelic Drugs Sales (K Units) by Type (2019-2024)
Table 25. Global Psychedelic Drugs Sales Market Share by Type (2019-2024)
Table 26. Global Psychedelic Drugs Market Size (M USD) by Type (2019-2024)
Table 27. Global Psychedelic Drugs Market Size Share by Type (2019-2024)
Table 28. Global Psychedelic Drugs Price (USD/Unit) by Type (2019-2024)
Table 29. Global Psychedelic Drugs Sales (K Units) by Application
Table 30. Global Psychedelic Drugs Market Size by Application
Table 31. Global Psychedelic Drugs Sales by Application (2019-2024) & (K Units)
Table 32. Global Psychedelic Drugs Sales Market Share by Application (2019-2024)
Table 33. Global Psychedelic Drugs Sales by Application (2019-2024) & (M USD)
Table 34. Global Psychedelic Drugs Market Share by Application (2019-2024)
Table 35. Global Psychedelic Drugs Sales Growth Rate by Application (2019-2024)
Table 36. Global Psychedelic Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Global Psychedelic Drugs Sales Market Share by Region (2019-2024)
Table 38. North America Psychedelic Drugs Sales by Country (2019-2024) & (K Units)
Table 39. Europe Psychedelic Drugs Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Psychedelic Drugs Sales by Region (2019-2024) & (K Units)
Table 41. South America Psychedelic Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Psychedelic Drugs Sales by Region (2019-2024) & (K Units)
Table 43. COMPASS Pathways PLC Psychedelic Drugs Basic Information
Table 44. COMPASS Pathways PLC Psychedelic Drugs Product Overview
Table 45. COMPASS Pathways PLC Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. COMPASS Pathways PLC Business Overview
Table 47. COMPASS Pathways PLC Psychedelic Drugs SWOT Analysis
Table 48. COMPASS Pathways PLC Recent Developments
Table 49. Pfizer Psychedelic Drugs Basic Information
Table 50. Pfizer Psychedelic Drugs Product Overview
Table 51. Pfizer Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Pfizer Business Overview
Table 53. Pfizer Psychedelic Drugs SWOT Analysis
Table 54. Pfizer Recent Developments
Table 55. Eli Lilly Psychedelic Drugs Basic Information
Table 56. Eli Lilly Psychedelic Drugs Product Overview
Table 57. Eli Lilly Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. Eli Lilly Psychedelic Drugs SWOT Analysis
Table 59. Eli Lilly Business Overview
Table 60. Eli Lilly Recent Developments
Table 61. GlaxoSmithKline Psychedelic Drugs Basic Information
Table 62. GlaxoSmithKline Psychedelic Drugs Product Overview
Table 63. GlaxoSmithKline Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. GlaxoSmithKline Business Overview
Table 65. GlaxoSmithKline Recent Developments
Table 66. Cybin Inc Psychedelic Drugs Basic Information
Table 67. Cybin Inc Psychedelic Drugs Product Overview
Table 68. Cybin Inc Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. Cybin Inc Business Overview
Table 70. Cybin Inc Recent Developments
Table 71. Field Trip Health Psychedelic Drugs Basic Information
Table 72. Field Trip Health Psychedelic Drugs Product Overview
Table 73. Field Trip Health Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Field Trip Health Business Overview
Table 75. Field Trip Health Recent Developments
Table 76. ATAI Life Sciences Psychedelic Drugs Basic Information
Table 77. ATAI Life Sciences Psychedelic Drugs Product Overview
Table 78. ATAI Life Sciences Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. ATAI Life Sciences Business Overview
Table 80. ATAI Life Sciences Recent Developments
Table 81. NUMINUS WELLNESS Psychedelic Drugs Basic Information
Table 82. NUMINUS WELLNESS Psychedelic Drugs Product Overview
Table 83. NUMINUS WELLNESS Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. NUMINUS WELLNESS Business Overview
Table 85. NUMINUS WELLNESS Recent Developments
Table 86. MindMed Psychedelic Drugs Basic Information
Table 87. MindMed Psychedelic Drugs Product Overview
Table 88. MindMed Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. MindMed Business Overview
Table 90. MindMed Recent Developments
Table 91. HAVN Life Sciences Psychedelic Drugs Basic Information
Table 92. HAVN Life Sciences Psychedelic Drugs Product Overview
Table 93. HAVN Life Sciences Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. HAVN Life Sciences Business Overview
Table 95. HAVN Life Sciences Recent Developments
Table 96. Seelos Therapeutics Psychedelic Drugs Basic Information
Table 97. Seelos Therapeutics Psychedelic Drugs Product Overview
Table 98. Seelos Therapeutics Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Seelos Therapeutics Business Overview
Table 100. Seelos Therapeutics Recent Developments
Table 101. Jannsen Psychedelic Drugs Basic Information
Table 102. Jannsen Psychedelic Drugs Product Overview
Table 103. Jannsen Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Jannsen Business Overview
Table 105. Jannsen Recent Developments
Table 106. Acadia Pharmaceuticals Psychedelic Drugs Basic Information
Table 107. Acadia Pharmaceuticals Psychedelic Drugs Product Overview
Table 108. Acadia Pharmaceuticals Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Acadia Pharmaceuticals Business Overview
Table 110. Acadia Pharmaceuticals Recent Developments
Table 111. Intellipharmaceutics Psychedelic Drugs Basic Information
Table 112. Intellipharmaceutics Psychedelic Drugs Product Overview
Table 113. Intellipharmaceutics Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Intellipharmaceutics Business Overview
Table 115. Intellipharmaceutics Recent Developments
Table 116. Revive Therapeutics Psychedelic Drugs Basic Information
Table 117. Revive Therapeutics Psychedelic Drugs Product Overview
Table 118. Revive Therapeutics Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Revive Therapeutics Business Overview
Table 120. Revive Therapeutics Recent Developments
Table 121. Mydecine Innovations Group Psychedelic Drugs Basic Information
Table 122. Mydecine Innovations Group Psychedelic Drugs Product Overview
Table 123. Mydecine Innovations Group Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Mydecine Innovations Group Business Overview
Table 125. Mydecine Innovations Group Recent Developments
Table 126. Red Light Holland Psychedelic Drugs Basic Information
Table 127. Red Light Holland Psychedelic Drugs Product Overview
Table 128. Red Light Holland Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Red Light Holland Business Overview
Table 130. Red Light Holland Recent Developments
Table 131. Braxia Scientific Psychedelic Drugs Basic Information
Table 132. Braxia Scientific Psychedelic Drugs Product Overview
Table 133. Braxia Scientific Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Braxia Scientific Business Overview
Table 135. Braxia Scientific Recent Developments
Table 136. Mind Cure Health Psychedelic Drugs Basic Information
Table 137. Mind Cure Health Psychedelic Drugs Product Overview
Table 138. Mind Cure Health Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 139. Mind Cure Health Business Overview
Table 140. Mind Cure Health Recent Developments
Table 141. Entheon Biomedical Psychedelic Drugs Basic Information
Table 142. Entheon Biomedical Psychedelic Drugs Product Overview
Table 143. Entheon Biomedical Psychedelic Drugs Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 144. Entheon Biomedical Business Overview
Table 145. Entheon Biomedical Recent Developments
Table 146. Global Psychedelic Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 147. Global Psychedelic Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 148. North America Psychedelic Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 149. North America Psychedelic Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 150. Europe Psychedelic Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 151. Europe Psychedelic Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 152. Asia Pacific Psychedelic Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 153. Asia Pacific Psychedelic Drugs Market Size Forecast by Region (2025-2030) & (M USD)
Table 154. South America Psychedelic Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 155. South America Psychedelic Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 156. Middle East and Africa Psychedelic Drugs Consumption Forecast by Country (2025-2030) & (Units)
Table 157. Middle East and Africa Psychedelic Drugs Market Size Forecast by Country (2025-2030) & (M USD)
Table 158. Global Psychedelic Drugs Sales Forecast by Type (2025-2030) & (K Units)
Table 159. Global Psychedelic Drugs Market Size Forecast by Type (2025-2030) & (M USD)
Table 160. Global Psychedelic Drugs Price Forecast by Type (2025-2030) & (USD/Unit)
Table 161. Global Psychedelic Drugs Sales (K Units) Forecast by Application (2025-2030)
Table 162. Global Psychedelic Drugs Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Psychedelic Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Psychedelic Drugs Market Size (M USD), 2019-2030
Figure 5. Global Psychedelic Drugs Market Size (M USD) (2019-2030)
Figure 6. Global Psychedelic Drugs Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Psychedelic Drugs Market Size by Country (M USD)
Figure 11. Psychedelic Drugs Sales Share by Manufacturers in 2023
Figure 12. Global Psychedelic Drugs Revenue Share by Manufacturers in 2023
Figure 13. Psychedelic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Psychedelic Drugs Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Psychedelic Drugs Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Psychedelic Drugs Market Share by Type
Figure 18. Sales Market Share of Psychedelic Drugs by Type (2019-2024)
Figure 19. Sales Market Share of Psychedelic Drugs by Type in 2023
Figure 20. Market Size Share of Psychedelic Drugs by Type (2019-2024)
Figure 21. Market Size Market Share of Psychedelic Drugs by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Psychedelic Drugs Market Share by Application
Figure 24. Global Psychedelic Drugs Sales Market Share by Application (2019-2024)
Figure 25. Global Psychedelic Drugs Sales Market Share by Application in 2023
Figure 26. Global Psychedelic Drugs Market Share by Application (2019-2024)
Figure 27. Global Psychedelic Drugs Market Share by Application in 2023
Figure 28. Global Psychedelic Drugs Sales Growth Rate by Application (2019-2024)
Figure 29. Global Psychedelic Drugs Sales Market Share by Region (2019-2024)
Figure 30. North America Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Psychedelic Drugs Sales Market Share by Country in 2023
Figure 32. U.S. Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Psychedelic Drugs Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Psychedelic Drugs Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Psychedelic Drugs Sales Market Share by Country in 2023
Figure 37. Germany Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Psychedelic Drugs Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Psychedelic Drugs Sales Market Share by Region in 2023
Figure 44. China Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Psychedelic Drugs Sales and Growth Rate (K Units)
Figure 50. South America Psychedelic Drugs Sales Market Share by Country in 2023
Figure 51. Brazil Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Psychedelic Drugs Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Psychedelic Drugs Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Psychedelic Drugs Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Psychedelic Drugs Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Psychedelic Drugs Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Psychedelic Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Psychedelic Drugs Market Share Forecast by Type (2025-2030)
Figure 65. Global Psychedelic Drugs Sales Forecast by Application (2025-2030)
Figure 66. Global Psychedelic Drugs Market Share Forecast by Application (2025-2030)
